Moderna Inc. said it will reduce annual spending by about $1.5 billion by 2027 as the company continues to cut costs to ...

Kennedy and FDA Commissioner Marty Makary’s approach to assessing vaccines could put Covid boosters out of reach.

HHS and the National Institutes of Health are developing a project that involves producing vaccines from chemically inactivated whole viruses with the goal of making “universal” vaccines that protect ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by ...

“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...

Several current and former FDA employees who spoke to Inside Medicine on the condition of anonymity have come to see the ...

Public health experts worry the policy change would not only cast doubt on the safety and effectiveness of vaccines but would limit production and access. Separately, a decades-long pursuit of ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

The U.S. FDA is planning to require all new vaccines to undergo placebo-controlled trials before approval. Read more here.